RECRUITING Not applicable ClinicalTrials.gov

Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia

Sponsor: Nantes University Hospital • ClinicalTrials.gov ID: NCT06743529

Registry updated: 2026-09-01

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics. Initiating antibiotic therapy immediately after bacteriological sampling (immediate strategy) may expose uninfected patients to unnecessary treatment, while waiting for bacteriological confirmation (conservative strategy) may delay ventilator-associated pneumonia in infected patients. The decision to start antibiotic therapy for ventilator-associated pneumonia takes three points into account: diagnostic probability, the risks to the patient if Antibiotic Therapy is delayed, and the risk of selection of resistant bacteria. Diagnostic probability is limited, given the subjective and non-specific nature of the diagnostic criteria, and only 30-50% of suspected cases are confirmed bacteriologically (whereas samples are only taken when the pre-test probability is sufficient). The risks associated with delayed antibiotic therapy are unknown, as few observational studies have directly assessed the impact of the timing of Antibiotic Therapy initiation on outcome (frequent confusion between delayed and inappropriate Antibiotic Therapy). Iregui et al. found that delaying Antibiotic Therapy by more than 24 hours was associated with higher mortality. However, more recent before-and-after studies have shown that the conservative strategy was associated with lower mortality, more frequently appropriate initial Antibiotic Therapy and shorter duration of Antibiotic Therapy. Similarly, in a recent before-and-after study by our team, initiating antibiotic therapy only upon microbiological confirmation of ventilator-associated pneumonia without septic shock or severe acute respiratory distress syndrome was not associated with an increase in ventilation time, length of stay or excess mortality at D28; but was associated with antibiotic therapy that was more often appropriate (DELAVAP, MARTIN et al, Annals of Intensive Care, 2024). Finally, the recent multicenter TARPP pilot study in surgical intensive care suggests that antibiotic therapy initiated on the basis of microbiological data in patients with suspected ventilator-associated pneumonia not requiring vasopressor support is not associated with a poorer outcome than immediate antibiotic therapy without documentation (the only randomized study on this subject). Antibiotic Therapy for suspected ventilator-associated pneumonia that is not subsequently confirmed is an unnecessary use of antibiotics and carries a risk of selection of resistant bacteria, with adverse effects on public health. It has been reported that a conservative Antibiotic Therapy prescription strategy for intensive care units -acquired infections reduces Antibiotic Therapy use and the incidence of acquired β-lactamase-producing Enterobacteriaceae infections. Overall, in patients with suspected ventilator-associated pneumonia but no signs of clinical severity, given the uncertainty about attributable mortality and concerns about bacterial resistance, the evaluation of the conservative Antibiotic Therapy strategy is reasonable. Some French intensive care units already delay Antibiotic Therapy until confirmation of ventilator-associated pneumonia, except in patients with severe hypoxemia or the need for vasopressor support.

Interventions

control group (Procedure)
immediate empiric Antibiotic Therapy (started within 1 hour after randomization) with antibiotic(s) chosen by the bedside physician based on time of ventilator-associated pneumoniaoccurrence, risk of antimicrobial resistance, local ecology, and local protocol. If the respiratory samples are negative, Antibiotic Therapy will be stopped. If ventilator-associated pneumonia is confirmed by positive samples, Antibiotic Therapy active against the recovered bacterial specie(s) will be given for a total of 7 days.
Conservative strategy (Procedure)
No Antibiotic Therapy until receipt of the respiratory sample culture and/or polymerase chain reaction results. If these results are negative, no Antibiotic Therapy is given. If they are positive (confirmed ventilator-associated pneumonia), Antibiotic Therapy is started as appropriate for the bacterial specie(s) detected by culture and/or polymerase chain reaction, without considering gram-stain results and without waiting for antimicrobial susceptibility testing results, and continued for a total of 7 days of Antibiotic Therapy active against the identified bacterial specie(s).

Eligibility criteria

Inclusion Criteria: * Invasive mechanical ventilation for longer than 48 hours * Respiratory sample collection taken less than two hours ago (at physician discretion, according to local protocol) for a first episode of suspected ventilator-associated pneumonia (meeting the following prespecified criteria) : * new or changing chest X-ray infiltrates * plus at least two of the following: * body temperature ≥38°C or ≤35.5°C, * blood leukocyte count \>12 000/µL or \<4000/µL, * purulent tracheobronchial aspirate. * Age ≥18 years * Informed consent from the patient or next of kin to participation in the trial, or emergency procedure if no next of kin is available * Patients affiliated to a social security system Non-inclusion Criteria: * Criteria for severe ventilator-associated pneumonia defined as: * Vasopressor therapy for onset of septic shock around the time of ventilator-associated pneumonia suspicion * Onset or severe worsening of hypoxemia (PaO2/FiO2\<150 with 60% FiO2 and 10 mm H2O peak expiratory pressure, or patient on veno-venous extracorporeal membrane oxygenation) * Immunosuppression defined as : * leukocytes \<1G/L or neutrophils \<0,5 G/L * within the last 3 months * hematopoietic stem-cell transplant or organ transplant with chronic immunosuppressant therapy * HIV infection with CD4\<50/mm3 * chronic corticosteroid use (\>0.5 mg/kg day for at least one month within the last three months). * Patient already on Antibiotic Therapy of predicted duration ≥4 weeks (endocarditis, spondylodiscitis, abscess...) * Previous ventilator-associated pneumonia suspicion with sampling and/or Antibiotic Therapy for suspected ventilator-associated pneumonia * Previous inclusion in the trial * Patient included in an interventional study on ventilator-associated pneumonia management with the same primary endpoint. * Pregnancy, recent delivery, or breastfeeding * Correctional facility inmate, adult under guardianship * Patient under legal protection * Life expectancy less than 48 h and/or decision not to treat potential pneumonia acquired under mechanical ventilation in the context of limiting/discontinuing treatment. * Organ donor reanimation

Conditions

Ventilator-Associated Pneumonia (VAP)

Locations

CHU Angers — Angers, France, France
CH Angoulème — Angoulème, France, France
CH Argenteuil — Argenteuil, France, France
CHU Nantes — Nantes, France, France
CH d'Arles — Arles, France
CH Avignon — Avignon, France
Hôpital Nord Franche Comté — Belfort, France
CHU de Bordeaux — Bordeaux, France
CHU de Bordeaux — Bordeaux, France
CH Simone Veil — Cannes, France
CH Public du Cotentin — Cherbourg, France
CH Cholet — Cholet, France
CHU Clermont-Ferrand — Clermont-Ferrand, France
CH Dax — Dax, France
CHU Dijon — Dijon, France
APHP - Hôpital Raymond Poincaré — Garches, France
CHD Vendée — La Roche-sur-Yon, France
CH Versailles — Le Chesnay, France
CH Le Mans — Le Mans, France
CH Emile Roux — Le Puy-en-Velay, France
CHRU Lille — Lille, France
GHB Sud- Hôpital de Lorient — Lorient, France
CHU de Lyon - Hôpital Edouard Herriot — Lyon, France
Hôpital Européen Marseille — Marseille, France
CH de Melun — Melun, France
CH de Mont de Marsan — Mont-de-Marsan, France
CHU Nice -Hôpital Pasteur — Nice, France
CHU Nice - Hôpital de l'Archet — Nice, France
CHR d'Orléans — Orléans, France
APHP - Hôpital Cochin — Paris, France
APHP - Hôpital Tenon — Paris, France
CH de Pau — Pau, France
CHU Rennes — Rennes, France
CH de Saint-Nazaire — Saint-Nazaire, France
CH de Saint-Malo — St-Malo, France
CHRU de Strasbourg - Nouvel Hôpital Civil — Strasbourg, France
CHRU de Strasbourg -Hôpital de Hautepierre — Strasbourg, France
Hôpital Foch — Suresnes, France
CHRU De Tours — Tours, France
CH de Valenciennes — Valenciennes, France
CH Bretagne Atlantique — Vannes, France
CHU La Guadeloupe — Pointe-à-Pitre, Guadeloupe

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment